Skip to main content
OpenTrials
Completed

NCT Number: NCT05164406

Impact of Blood Salvage Therapy on Outcomes After Oncologic Liver Surgery

A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections. Recurrence, survival, allogenic transfusion rates and surgical outcomes are compared with a representative historic cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Neoplasms Digestive System Diseases Digestive System Neoplasms Liver Diseases Neoplasms Neoplasms by Site

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, J1G5N3, Canada

About this study

Blood salvage therapy in oncologic liver surgery is seldom used based on unproven concerns about the safety of the technique regarding potential cancer dissemination or recurrence. Nevertheless, the technique has proven advantages in other surgical settings regarding the allogenic transfusion outcomes. Allogenic blood transfusion has been scientifically proven to worsen prognosis in oncologic surgery. This study compares a cohort of patients systematically exposed the blood salvage therapy to one comparable cohort without the therapy and outcomes regarding transfusion rates, post-operative Hb measurement, recurrence, overall survival, and post-operative adverse events.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult Oncologic liver surgery scheduled in our institution

Exclusion criteria

  • Condition precluding consent for trial Pregnancy

Treatment and study plan

Blood salvage therapy

Procedure

In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met

Primary outcomes

  1. Recurrence free survival

    Time frame: 18 months

  2. Overall survival

    Time frame: 18 months

  3. Transfusion

    Time frame: Up to 30 days after surgery

    Allogenic blood products requirements

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Registry information

Official study title

Impact of Blood Salvage Therapy During Oncologic Liver Surgeries on Allogenic Transfusion Events, Survival and Recurrence

Important dates

Study start
2018
Primary completion
2019
Study completion
2021
First posted
Dec 20, 2021
Registry last updated
May 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.